Falling Short: Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis
This report presents new evidence to document the challenges curren...
Publications
View as listFeatured Publications
2012 TB Alliance Annual ReportRealizing the Promise
2013 World TB Day Newsletter
New TB Regimens: What Countries WantThe Value Proposition of Existing and New First-Line Regimens for Drug-Susceptible Tuberculosis
Based on an analysis of interviews with 211 key stakeholders in Bra...
Other Publications
Pathway to Patients
Pathway to Patients is the first comprehensive analysis of...
Policy on the Compassionate / Emergency Use of Experimental TB Alliance Drugs
This document outlines the policy of the Global Alliance for TB Dru...
The Economics of TB Drug Development
The Economics of TB Drug Development report discusses key factors i...
Scientific Blueprint for TB Drug Development
The Scientific Blueprintfor TB Drug Development presents the following...
Annual Reports & Statements
2012 TB Alliance Annual Report
Realizing the Promise
2011 TB Alliance Financial Statement
2011 TB Alliance Annual Report
Crossing Thresholds
2010 TB Alliance Financial Statement
2010 TB Alliance Annual Report
More Than Ever
TB Alliance 2009 Financial Statement
Research Papers
Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis
Kathy Williams, Austin Minkowski, Opokua Amoabeng, Charles A. Peloquin, Dinesh Taylor, Koen Andries, Robert S. Wallis, Khisimuzi E. Mdluli, and Eric L. Nuermberger
Identification of Less Lipophilic Riminophenazine Derivatives for the Treatment of Drug-Resistant Tuberculosis
Zhang D, Lu Y, Liu K, Liu B, Wang J, Zhang G, Zhang H, Liu Y, Wang B, Zheng M, Fu L, Hou Y, Gong NB, Lv Y, Li C, Cooper CB, Upton AM, Yin D, Ma Z, Huang H.
Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis
Rokeya Tasneen,Si-Yang Li, Charles A. Peloquin, Dinesh Taylor, Kathy N. Williams, Koen Andries, Khisimuzi E. Mdluli, and Eric L. Nuermberger
New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
Christian Lienhardt, Mario Raviglione, Mel Spigelman, Richard Hafner, Ernesto Jaramillo, Michael Hoelscher, Alimuddin Zumla, and Jan Gheuens7
Tuberculosis regimen change in high-burden countries
W. A. Wells, N. Konduri,C. Chen, D. Lee, H. R. Ignatius, E. Gardiner, N. R. Schwalbe
Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making
William A Wells and Alan Brooks
Site by Darby Communications
© 2013 Global Alliance for TB Drug Development